Last quarter (Q4 2022), Tenaya Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Tenaya Therapeutics's net income was $-33.52M. See Tenaya Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 125.62M	$ 125.62M	$ 72.81M	$ 38.91M	$ 27.71M
Operating Income	$ -125.62M	$ -125.62M	$ -72.81M	$ -38.91M	$ -27.71M
Net Non Operating Interest Income Expense	$ 1.95M	$ 1.95M	$ 108.00K	$ 87.00K	$ 453.00K
Other Income Expense	$ 2.00K	$ 2.00K	$ -23.00K	$ 430.00K	$ 1.03M
Pretax Income	$ -123.67M	$ -123.67M	$ -72.72M	$ -38.40M	$ -26.23M
Tax Provision	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -123.67M	$ -123.67M	$ -72.72M	$ -38.40M	$ -26.23M
Basic EPS	$ -2.79	$ -2.76	$ -4.10	$ -1.42	$ -0.97
Diluted EPS	$ -2.79	$ -2.76	$ -4.10	$ -1.42	$ -0.97
Basic Average Shares	$ 179.29M	$ 44.82M	$ 17.73M	$ 27.07M	$ 27.07M
Diluted Average Shares	$ 179.29M	$ 44.82M	$ 17.73M	$ 27.07M	$ 27.07M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 125.62M	$ 125.62M	$ 72.81M	$ 38.91M	$ 27.71M
Net Income From Continuing And Discontinued Operation	$ -123.67M	$ -123.67M	$ -72.72M	$ -38.40M	$ -26.23M
Normalized Income	$ -123.67M	$ -123.67M	$ -72.72M	$ -38.40M	$ -26.23M
Interest Expense	-	-	-	-	-
EBIT	$ -125.62M	$ -125.62M	$ -72.81M	$ -38.91M	$ -27.71M
EBITDA	$ -119.15M	$ -119.15M	$ -69.84M	$ -36.43M	$ -25.72M

Currency in USD

Tenaya Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing